| id | Study | Lib. in paper | Exposition period | Study type  | 
                Control type  | 
                Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S13773 R53891  | 
                Baalbaki, 2020 | Neonatal composite (fetal death, NICU, neonatal death, intraventricular hemorrhage, sepsis, necrotizing enterocolitis, ...) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indication HCQ: Systemic lupus erythematosus (SLE) | 0.62 [0.25;1.57] C | 18/47 15/30 | 33 | 47 | 
                    
                    
                         | 
                ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13713 R53412  | 
                Mollerach, 2019 | Neonatal complications (NOS) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) | 3.87 [0.07;205.70] C | 0/12 0/45 | 0 | 12 | 
                    
                    
                         | 
                ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13651 R52961  | 
                Cooper (controls exposed to TNF-I), 2014 | Neonatal complications | 1st trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) | 
                    1.01 [0.32;3.20] C  excluded (control group)  | 
                
                14/194 4/56 | 18 | 194 | 
                    
                    
                         | 
                ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13652 R52991  | 
                Cooper (controls unexposed, sick), 2014 | Neonatal complications | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) | 1.82 [0.72;4.63] C | 14/194 7/171 | 21 | 194 | 
                    
                    
                         | 
                ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.13 [0.47;2.74] | 54 | 253 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 13651